Nature Reviews Rheumatology
Издатель: Springer Nature · ISSN 1759-4790,1759-4804 · 8 статей
-
Development of treatments for sarcopenia: new challenges, opportunities and perspectives
Nature Reviews Rheumatology, Published online: 16 November 2026; doi:10.1038/s41584-026-01457-4 This Perspective presents contemporary perspectives on advances and challenges in the development of pharmacological interventions for...
-
Decoding treatment non-response in spondyloarthritis
Nature Reviews Rheumatology, Published online: 13 November 2026; doi:10.1038/s41584-026-01455-6 Treatment non-response in spondyloarthritis is heterogeneous rather than a single phenomenon. This Review proposes a framework that...
-
The pathogenesis of systemic manifestations in Sjögren disease
Nature Reviews Rheumatology, Published online: 13 November 2026; doi:10.1038/s41584-026-01461-8 The authors of this Review provide a comprehensive overview of the pathogenesis of the systemic manifestations of Sjögren disease (SjD)....
-
GLADEL–PANLAR clinical practice guidelines for the management of systemic lupus erythematosus: 2025 update
Nature Reviews Rheumatology, Published online: 12 November 2026; doi:10.1038/s41584-026-01450-x These Evidence-Based Guidelines update the 2018 Latin American Group for the Study of Lupus–Pan-American League of Associations for...
-
Ianalumab reduces Sjögren disease activity
Nature Reviews Rheumatology, Published online: 10 November 2026; doi:10.1038/s41584-026-01466-3 In patients with active Sjögren disease, treatment with ianalumab 300 mg monthly reduced disease activity, but not symptom scores, more than...
-
Rituximab not superior to azathioprine for EGPA remission maintenance
Nature Reviews Rheumatology, Published online: 10 November 2026; doi:10.1038/s41584-026-01465-4 In the MAINRITSEG clinical trial, treatment with rituximab did not confer an advantage over azathioprine for the maintenance of remission in...
-
Immune checkpoint inhibitor-associated inflammatory arthritis
Nature Reviews Rheumatology, Published online: 06 November 2026; doi:10.1038/s41584-026-01452-9 Immune checkpoint inhibitor-associated inflammatory arthritis is the most common rheumatic immune-related adverse event. In this Review, the...
-
Novel platform recapitulates microbe–gut–cartilage axis in vitro
Nature Reviews Rheumatology, Published online: 05 November 2026; doi:10.1038/s41584-026-01460-9 Researchers have develped a microbe–gut–cartilage axis-on-a-chip platform to investigate the pathogenic mechanisms underlying osteoarthritis.